A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza A virus vaccine-H5N1 (Primary) ; Aluminium hydroxide; Glycopyranosyl lipid adjuvant; Glycopyranosyl lipid adjuvant
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 17 Apr 2013 Interim results published in a Medicago media release and presented at the World Vaccine Congress.
    • 09 Apr 2013 Positive interim results will be presented at the World Vaccine Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top